We are live on ! Find out more
TECP

Trails Edge Capital Partners Portfolio holdings

AUM $630M
This Fund
S&P 500
This Quarter Est. Return
+16.76%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$630M
AUM Growth
+$193M
Cap. Flow
+$123M
Cap. Flow %
19.54%
Top 10 Hldgs %
50.32%
Holding
40
New
13
Increased
10
Reduced
7
Closed
5
Avg Time Held Equity + Options
0.9 quarters
Top 10 Avg Time Held Equity + Options
0.9 quarters
Top 20 Avg Time Held Equity + Options
0.9 quarters
Avg Time Held Equity only
0.9 quarters
Top 10 Avg Time Held Equity only
0.9 quarters
Top 20 Avg Time Held Equity only
0.9 quarters

Top Buys

Rank Stock Value
1
TRAX
First Tracks Biotherapeutics
TRAX
+$28.3M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$28M
3
INSM icon
Insmed
INSM
+$27.9M
4
KLRA
Kailera Therapeutics
KLRA
+$21.6M
5
INCY icon
Incyte
INCY
+$15.4M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$38.5M
2
DFTX
Definium Therapeutics
DFTX
+$32.9M
3
RCUS icon
Arcus Biosciences
RCUS
+$22.6M
4
RVMD icon
Revolution Medicines
RVMD
+$18.9M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.15%
2 Financials 0.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IVA
26
Inventiva
IVA
$747M
$10M 1.6%
2,657,997
– –
2025 Q4
2 quarters
CAMP icon
27
CAMP4 Therapeutics
CAMP
$237M
$8.45M 1.34%
1,932,937
-6,626
-0.3% -$28.6K
2025 Q4
2 quarters
ALT icon
28
Altimmune
ALT
$508M
$8.09M 1.28%
+2,660,000
New +$7.94M
2026 Q2
0 quarters
NERV icon
29
Minerva Neurosciences
NERV
$152M
$7.88M 1.25%
1,419,000
– –
2026 Q1
1 quarter
PMN icon
30
ProMIS Neurosciences
PMN
$86.2M
$7.33M 1.16%
557,103
– –
2026 Q1
1 quarter
OKUR
31
OnKure Therapeutics
OKUR
$97.6M
$6.56M 1.04%
+1,438,456
New +$6.17M
2026 Q2
0 quarters
FBRX
32
DELISTED
Forte Biosciences
FBRX
$5.81M 0.92%
+273,181
New +$6.48M
2026 Q2
0 quarters
RACC
33
Research Alliance Corp III
RACC
$92.6M
$5.35M 0.85%
+500,000
New +$5.21M
2026 Q2
0 quarters
VTVT icon
34
vTv Therapeutics
VTVT
$123M
$3.21M 0.51%
85,192
-54,386
-39% -$1.89M
2025 Q4
2 quarters
IMA
35
ImageneBio Inc
IMA
$48.1M
$1.66M 0.26%
+282,004
New +$1.59M
2026 Q2
0 quarters
IMVT icon
36
Immunovant
IMVT
$6.29B
– –
-414,054
Closed -$10.3M –
DFTX
37
Definium Therapeutics
DFTX
$4.96B
– –
-1,738,110
Closed -$32.9M –
PCVX icon
38
Vaxcyte
PCVX
$10.6B
– –
-662,470
Closed -$38.5M –
RCUS icon
39
Arcus Biosciences
RCUS
$3.11B
– –
-1,047,935
Closed -$22.6M –
XENE icon
40
PUT
Xenon Pharmaceuticals
XENE
$3.53B
– –
-200,000
Closed -$11.6M –
1
2

Similar funds

SJIC
St. James Investment Company Southlake, Texas $630M AUM 12.48% 1-Year Est. Return
SFO
Stenger Family Office Naperville, Illinois $629M AUM 25.67% 1-Year Est. Return
PPC
Park Place Capital Homewood, Alabama $629M AUM 18.27% 1-Year Est. Return
ACGA
Atlanta Consulting Group Advisors Atlanta, Georgia $631M AUM 22.46% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
MC
Machina Capital Paris, France $631M AUM 11.37% 1-Year Est. Return
GPTE
Generali Powszechne Towarzystwo Emerytalne Warsaw, Poland $631M AUM 32.98% 1-Year Est. Return
KNW
Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Trails Edge Capital Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Trails Edge Capital Partners held 40 positions worth $630M, up 44% from $437M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Trails Edge Capital Partners deployed $123M of net new capital in Q2 2026, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was First Tracks Biotherapeutics: 1,514,000 shares worth $30.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Revolution Medicines, an estimated $18.9M trimmed.

  • Trails Edge Capital Partners's largest Q2 2026 buy was First Tracks Biotherapeutics: 1,514,000 shares worth $30.5M.
  • Trails Edge Capital Partners added most to Design Therapeutics in Q2 2026, an estimated $14.3M increase.
  • Trails Edge Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $18.9M.
  • Trails Edge Capital Partners fully exited Vaxcyte in Q2 2026, selling an estimated $38.5M.
  • Trails Edge Capital Partners's ten largest holdings make up 50% of its $630M portfolio in Q2 2026.
  • Trails Edge Capital Partners opened 13 new positions and closed 5 in Q2 2026.
  • Trails Edge Capital Partners's portfolio value rose 44% quarter-over-quarter to $630M.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.